Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 4142.TW and 80,000+ other tickers.
See exactly how 4142.TW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4142.TW and 80,000+ other tickers.
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract…
No recent news available.